Trimetazidine modified release in treatment of patients with the serious course of chronic ischemic heart disease: from the theory to real clinical practice

Cover Page

Cite item

Full Text

Abstract

The paper considers modern conceptions about the role of citoprotective therapy in persons with ischemic heart disease. Special attention is given to the justification of Trimetazidine modified release (TMZ MV) application in patients with severe multi-vessel coronary lesions in conjunction with left ventricular systolic dysfunction. There described the clinical case with emphasis on possibility of inclusion in conservative treatment scheme of TMZ MB to poly morbid elderly patient with severe ischemic heart disease.

About the authors

A. V Barsukov

Military medical academy named after S.M.Kirov, Saint−Petersburg

д-р мед. наук, проф., зам. нач. каф. госпитальной терапии

D. V Glukhovskoy

Military medical academy named after S.M.Kirov, Saint−Petersburg

канд. мед. наук, асс. каф. госпитальной терапии

References

  1. Васюк Ю.А., Шальнова С.А., Школьник Е.Л. и др. Исследование ПРИМА. Сравнение клинического эффекта триметазидина MB у мужчин и женщин. Кардиология. 2011; 51 (6): 11-5.
  2. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14 (7): 379-472.
  3. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4: CD003614.
  4. Clarke B, Wyatt K.M, Mc Cormack J.G. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J Mol Cell Cardiol 1996; 28 (2): 341-50.
  5. Cohn J.N, Levine T.B, Olivari M.T et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984: 311 (13): 819-23.
  6. Danchin N, Marzilli M, Parkhomenko A et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta - analysis. Cardiology 2011; 120 (2): 59-72.
  7. Deleiris J, Boucher F. Rationale for trimetazidine administration in myocardial - ischemia reperfusion syndrome. Eur Heart J 1993; 14 (Suppl. G): 34-40.
  8. Dell’Halia L, Sabri A. Activation of the renin - angiotensin system in hypertrophy and heart failure. Heart Failure. Ed. D.Mann. Philadelphia: Saunders 2004: 129-44.
  9. Di Napoli P, Chierchia S, Taccardi A.A et al. Trimetazidine improves post - ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric Oxide-Biol Ch 2007; 16 (2): 228-36.
  10. El-Kady T, El-Sabban K, Gabaly M et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005; 5: 271-8.
  11. Fox K, Garcia M.A, Ardissino D et al. Guidelines on the management of stable angina pectoris: the Task Force of the European Society of Cardiology. Eur Heart J 2006; 27 (11): 1341-81.
  12. Fragasso G, Rosano G, Baek S.H et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol 2013; 163 (3): 320-5.
  13. Gao D, Ning N, Niu X et al. Trimetazidine: a meta - analysis of randomised controlled trials in heart failure. Heart 2011; 97 (4): 278-86.
  14. Hasegawa K, Iwai-Kanai E, Sasayama S. Neurohormonal regulation of myocardial cell apoptosis during the development of heart failure. J Cell Physiol 2001; 186 (1): 11-8.
  15. Imamura Y, Ando H, Ashihara T, Fukuyama T. Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. J Am Coll Cardiol 1996; 28 (2): 371-5.
  16. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc Res 2009; 81 (3): 412-9.
  17. Iyengar S.S, Rosano G.M. Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction: a preliminary study (METRO). Am J Cardiovasc Drugs 2009; 9 (5): 293-7.
  18. Kantor P.F, Lucien A, Kozak R et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial longchain - ketoacyl coenzyme A thiolase. Circ Res 2000; 86 (5): 580-8.
  19. Kaye D, Lefkovits J, Jennings G et al. Adverse consequence of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26 (5): 1257-63.
  20. Kiyosue T, Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea - pig ventricular myocytes. J Mol Cell Cardiol 1986; 18 (2): 1301-11.
  21. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25 (8): 634-41.
  22. Levin E.R, Gardner D.G, Samson W.K. Mechanisms of disease - Natriuretic peptides. New Engl J Med 1998; 339: 321-8.
  23. Lopaschuk G.D, Ussher J.R, Folmes C.D et al. Myocardial Fatty Acid Metabolism in Health and Disease. Physiol Rev 2010; 90 (1): 207-58.
  24. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology Eur Heart J 1997; 18: 314-413.
  25. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91 (11): 988-98.
  26. Mann D.L. Activation of inflammatory mediators in heart failure. Heart Failure. Philadelphia: Saunders 2004: 159-80.
  27. Margulies K.B, Houser S.R. Myocyte abnormalities in human heart failure. Heart Failure Philadelphia: Saunders 2004: 41-98.
  28. Marzilli M, Klein W.W. Efficacy and tolerability of trimetazidine in stable angina: a meta - analysis of randomized, double - blind, controlled trials. Coron Artery Dis 2003; 14 (2): 171-9.
  29. Masmoudi K, Masson H, Gras V et al. Extrapyramidal adverse drug reactions associated with trimetazidine: a series of 21 cases. Fundam Clin Pharmacol 2011.
  30. Montastruc J.L, Sommet A, Olivier P et al. Drugs, Parkinson’s disease and parkinsonian syndroms: recent advances in pharmacovigilance. Therapie 2006; 61 (1): 29-38.
  31. Narula J, Pandley P, Arbustini E et al. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999; 96 (14): 8144-9.
  32. Opie L.H. The metabolic vicious cycle in heart failure. Lancet 2004;364 (9447): 1733-4.
  33. Ruixing Y, Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia - reperfusion. Transl Res 2007; 149 (3): 152-60.
  34. Schonfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med 2008; 45 (3): 231-41.
  35. Stanley W.C, Lopaschuk G.D, Hall J.L et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions - Potential for pharmacological interventions. Cardiovasc Res 1997; 33 (2): 243-57.
  36. Wallhaus T.R, Taylor M, Degrado T.R. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103 (20): 2441-6.
  37. Williams F.M, Tanda K, Kus M et al. Trimetazidine inhibits neutrophil accumulation after myocardial - ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22 (6): 828-33.
  38. Zhang L, Lu Y, Jiang H et al. Additional use of Trimetazidine in patients with chronic heart failure: a meta - analysis. J Am Coll Cardiol 2012; 59 (10): 913-22.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies